CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −6,679 | $242.42 | $1.6M | 204,637 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −9,264 | $243.20 | $2.3M | 195,373 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −3,966 | $244.22 | $969K | 191,407 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,228 | $245.35 | $1.3M | 186,179 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −444 | $245.92 | $109K | 185,735 |
| 2024-04-05 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,613 | 232,526 | ||
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Option exercise 10b5-1 | +18,537 | $9.45 | $175K | 477,536 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −4,200 | $240.88 | $1.0M | 473,336 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −5,619 | $241.85 | $1.4M | 467,717 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −3,085 | $242.71 | $749K | 464,632 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −435 | $244.01 | $106K | 464,197 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −2,734 | $245.06 | $670K | 461,463 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −1,653 | $246.01 | $407K | 459,810 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −711 | $247.23 | $176K | 459,099 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −100 | $248.23 | $25K | 458,999 |
| 2024-04-04 | Taub Rebecca Pres., R&D, and CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,537 | 106,746 | ||
| 2024-04-04 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +18,710 | $9.45 | $177K | 204,445 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −6,273 | $241.07 | $1.5M | 198,172 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,299 | $242.25 | $1.3M | 192,873 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,467 | $243.00 | $356K | 191,406 |
Page 32 of 82 · 1,629 trades